• Home
  • Study Details

A Randomized, Double-Blind, Phase III Trial in First-Line HER2-Positive Metastatic Breast Cancer

To study how well certain chemotherapy drugs will work in conjunction with Immunotherapy drugs in treating patients with breast cancer that has spread to other parts of the body.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female


North Carolina (Edgecombe, Nash)

What will be asked of you

You will be seen in person for screening, consent, all of infusion treaments and lab work. Scheduled imaging as required by study.

In-person visits : 50 +
Total length of participation : 9 years

Looking for Specific Volunteers

Able to participate:

  • Have a diagnosis of metastatic disease
  • Tumor specimen, at time of diagnosis, must be determined to be HER2-positive and have testing for ER and PgR testing
  • Have imaging of the chest, abdomen, and pelvis

Not eligible if:

  • Have known leptomeningeal carcinomatosis
  • Have metastatic disease limited to the CNS
  • Have a history of systemic anti-cancer therapy
  • Uncontrolled hypertension
  • Have a history of or active cardiac disease

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Jayadev Manikkam umakanthan
UNC Hospitals - Nash

Study Topics

Cancer (Breast)
Women's Health
Men's Health

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.